Please enable JavaScript to continue using this application.

Compare $PYXS vs $QTTB | Chartloom

Compare

$PYXS vs $QTTB

Pyxis Oncology Inc · Q32 Bio Inc

PYXS

Pyxis Oncology Inc

QTTB

Q32 Bio Inc

Compare $PYXS vs $QTTB

Comparing Pyxis Oncology Inc and Q32 Bio Inc

PYXSPyxis Oncology Inc

QTTBQ32 Bio Inc

PYXSPyxis Oncology Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-14.2%

YTD performance

76.5%

52W performance

-30.2%

FCF yield

-40.3%

QTTBQ32 Bio Inc

Market cap

$248M

P/E (TTM)

8.22x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

142.4%

52W performance

178.9%

FCF yield

-8.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PYXS

QTTB

Detailed metrics comparison

PYXS

Pyxis Oncology Inc

QTTB

Q32 Bio Inc

Market Cap

PYXS$168M

QTTB$248M

Enterprise Value

PYXS$150M

QTTB$142M

Price

PYXS$2.03

QTTB$8.34

P/E Ratio

PYXSN/A

QTTB8.22x

P/S Ratio

PYXS15.26x

QTTB4.62x

EV/Sales

PYXS13.55x

QTTB2.64x

EV/EBITDA

PYXS0.00x

QTTB3.69x

P/B Ratio

PYXS15.60x

QTTB2.31x

P/FCF Ratio

PYXSN/A

QTTBN/A

EV/FCF

PYXS-2.20x

QTTB-7.16x

PEG Ratio

PYXSN/A

QTTBN/A

Forward P/E (NTM)

PYXSN/A

QTTBN/A

Forward P/S (NTM)

PYXSN/A

QTTBN/A

Revenue (TTM)

PYXS$11M

QTTB$54M

Revenue Growth (YoY)

PYXS-14.2%

QTTBN/A

Forward Rev Growth

PYXS14187.3%

QTTB215.1%

Gross Margin (TTM)

PYXS78.4%

QTTB0.0%

Operating Margin (TTM)

PYXS0.0%

QTTB85.4%

EBITDA Margin (TTM)

PYXS-580.0%

QTTB71.6%

Net Margin (TTM)

PYXS-593.0%

QTTB93.7%

FCF Margin (TTM)

PYXS-615.3%

QTTB-36.9%

Net Income (TTM)

PYXS$-65M

QTTB$50M

FCF (TTM)

PYXS$-68M

QTTB$-20M

EPS (TTM)

PYXS-$1.03

QTTB$0.00

ROE (TTM)

PYXS-10177.0%

QTTB137.4%

ROA (TTM)

PYXS-6981.0%

QTTB45.1%

ROIC (TTM)

PYXS-10171.0%

QTTB111.6%

Cash

PYXS$19M

QTTB$106M

Debt

PYXS$0

QTTB$0

Net Cash/Debt

PYXS$19M

QTTB$106M

Current Ratio (TTM)

PYXS1.34x

QTTB20.30x

Quick Ratio (TTM)

PYXS1.25x

QTTB19.80x

Debt/Equity (TTM)

PYXS0.00x

QTTB2.29x

Debt/Assets (TTM)

PYXS0.0%

QTTB0.0%

Interest Coverage (TTM)

PYXSN/A

QTTBN/A

Net Debt/EBITDA (TTM)

PYXS0.00x

QTTB0.00x

Beta

PYXS1.37

QTTB0.50

52W Performance

PYXS-30.2%

QTTB178.9%

YTD Performance

PYXS76.5%

QTTB142.4%

% from 52W High

PYXS-63.4%

QTTB-64.6%

% from 52W Low

PYXS97.1%

QTTB337.8%

Asset Turnover (TTM)

PYXS0.00x

QTTB0.87x

FCF Yield (TTM)

PYXS-40.3%

QTTB-8.0%

Earnings Yield (TTM)

PYXS-38.9%

QTTB20.3%

Dividend Yield (TTM)

PYXSN/A

QTTBN/A

Rule of 40

PYXS-629.5

QTTB-36.9

EV/GP/RG

PYXS0.00

QTTBN/A

Ticker research

View PYXS research View QTTB research

Metric	PYXS Pyxis Oncology Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$168M	$248M
Enterprise Value	$150M	$142M
Price	$2.03	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	15.26x	4.62x
EV/Sales	13.55x	2.64x
EV/EBITDA	0.00x	3.69x
P/B Ratio	15.60x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$11M	$54M
Revenue Growth (YoY)	-14.2%	N/A
Forward Rev Growth	14187.3%	215.1%
Profitability
Gross Margin (TTM)	78.4%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-580.0%	71.6%
Net Margin (TTM)	-593.0%	93.7%
FCF Margin (TTM)	-615.3%	-36.9%
Net Income (TTM)	$-65M	$50M
FCF (TTM)	$-68M	$-20M
EPS (TTM)	-$1.03	$0.00
ROE (TTM)	-10177.0%	137.4%
ROA (TTM)	-6981.0%	45.1%
ROIC (TTM)	-10171.0%	111.6%
Financial Health
Cash	$19M	$106M
Debt	$0	$0
Net Cash/Debt	$19M	$106M
Current Ratio (TTM)	1.34x	20.30x
Quick Ratio (TTM)	1.25x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.37	0.50
52W Performance	-30.2%	178.9%
YTD Performance	76.5%	142.4%
% from 52W High	-63.4%	-64.6%
% from 52W Low	97.1%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.87x
FCF Yield (TTM)	-40.3%	-8.0%
Earnings Yield (TTM)	-38.9%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-629.5	-36.9
EV/GP/RG	0.00	N/A
Ticker research	View PYXS research	View QTTB research

Valuation

P/E Ratio

QTTB

8.22x

P/S Ratio

QTTB

4.62x

PYXS

15.26x

EV/FCF

QTTB

-7.16x

PYXS

-2.20x

Growth & revenue

Revenue Growth TTM

PYXS

-14.2%

Forward Revenue Growth

PYXS

14187.3%

QTTB

215.1%

Profitability & performance

Gross Margin

PYXS

78.4%

QTTB

0.0%

ROE

QTTB

137.4%

PYXS

-10177.0%

FCF Yield %

QTTB

-8.0%

PYXS

-40.3%

52-Week Performance

QTTB

178.9%

PYXS

-30.2%

Detailed metrics comparison

PYXS

Pyxis Oncology Inc

QTTB

Q32 Bio Inc

Market Cap

PYXS$168M

QTTB$248M

Enterprise Value

PYXS$150M

QTTB$142M

Price

PYXS$2.03

QTTB$8.34

P/E Ratio

PYXSN/A

QTTB8.22x

P/S Ratio

PYXS15.26x

QTTB4.62x

EV/Sales

PYXS13.55x

QTTB2.64x

EV/EBITDA

PYXS0.00x

QTTB3.69x

P/B Ratio

PYXS15.60x

QTTB2.31x

P/FCF Ratio

PYXSN/A

QTTBN/A

EV/FCF

PYXS-2.20x

QTTB-7.16x

PEG Ratio

PYXSN/A

QTTBN/A

Forward P/E (NTM)

PYXSN/A

QTTBN/A

Forward P/S (NTM)

PYXSN/A

QTTBN/A

Revenue (TTM)

PYXS$11M

QTTB$54M

Revenue Growth (YoY)

PYXS-14.2%

QTTBN/A

Forward Rev Growth

PYXS14187.3%

QTTB215.1%

Gross Margin (TTM)

PYXS78.4%

QTTB0.0%

Operating Margin (TTM)

PYXS0.0%

QTTB85.4%

EBITDA Margin (TTM)

PYXS-580.0%

QTTB71.6%

Net Margin (TTM)

PYXS-593.0%

QTTB93.7%

FCF Margin (TTM)

PYXS-615.3%

QTTB-36.9%

Net Income (TTM)

PYXS$-65M

QTTB$50M

FCF (TTM)

PYXS$-68M

QTTB$-20M

EPS (TTM)

PYXS-$1.03

QTTB$0.00

ROE (TTM)

PYXS-10177.0%

QTTB137.4%

ROA (TTM)

PYXS-6981.0%

QTTB45.1%

ROIC (TTM)

PYXS-10171.0%

QTTB111.6%

Cash

PYXS$19M

QTTB$106M

Debt

PYXS$0

QTTB$0

Net Cash/Debt

PYXS$19M

QTTB$106M

Current Ratio (TTM)

PYXS1.34x

QTTB20.30x

Quick Ratio (TTM)

PYXS1.25x

QTTB19.80x

Debt/Equity (TTM)

PYXS0.00x

QTTB2.29x

Debt/Assets (TTM)

PYXS0.0%

QTTB0.0%

Interest Coverage (TTM)

PYXSN/A

QTTBN/A

Net Debt/EBITDA (TTM)

PYXS0.00x

QTTB0.00x

Beta

PYXS1.37

QTTB0.50

52W Performance

PYXS-30.2%

QTTB178.9%

YTD Performance

PYXS76.5%

QTTB142.4%

% from 52W High

PYXS-63.4%

QTTB-64.6%

% from 52W Low

PYXS97.1%

QTTB337.8%

Asset Turnover (TTM)

PYXS0.00x

QTTB0.87x

FCF Yield (TTM)

PYXS-40.3%

QTTB-8.0%

Earnings Yield (TTM)

PYXS-38.9%

QTTB20.3%

Dividend Yield (TTM)

PYXSN/A

QTTBN/A

Rule of 40

PYXS-629.5

QTTB-36.9

EV/GP/RG

PYXS0.00

QTTBN/A

Ticker research

View PYXS research View QTTB research

Metric	PYXS Pyxis Oncology Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$168M	$248M
Enterprise Value	$150M	$142M
Price	$2.03	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	15.26x	4.62x
EV/Sales	13.55x	2.64x
EV/EBITDA	0.00x	3.69x
P/B Ratio	15.60x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$11M	$54M
Revenue Growth (YoY)	-14.2%	N/A
Forward Rev Growth	14187.3%	215.1%
Profitability
Gross Margin (TTM)	78.4%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-580.0%	71.6%
Net Margin (TTM)	-593.0%	93.7%
FCF Margin (TTM)	-615.3%	-36.9%
Net Income (TTM)	$-65M	$50M
FCF (TTM)	$-68M	$-20M
EPS (TTM)	-$1.03	$0.00
ROE (TTM)	-10177.0%	137.4%
ROA (TTM)	-6981.0%	45.1%
ROIC (TTM)	-10171.0%	111.6%
Financial Health
Cash	$19M	$106M
Debt	$0	$0
Net Cash/Debt	$19M	$106M
Current Ratio (TTM)	1.34x	20.30x
Quick Ratio (TTM)	1.25x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.37	0.50
52W Performance	-30.2%	178.9%
YTD Performance	76.5%	142.4%
% from 52W High	-63.4%	-64.6%
% from 52W Low	97.1%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.87x
FCF Yield (TTM)	-40.3%	-8.0%
Earnings Yield (TTM)	-38.9%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-629.5	-36.9
EV/GP/RG	0.00	N/A
Ticker research	View PYXS research	View QTTB research